Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)

Edward Fox, MD, PhD
Director, MS Clinic of Central Texas
Central Texas Neurology Consultants, PA
Clinical Associate Professor, University of Texas Dell Medical School

Edward Fox, MD, PhD; Amy E. Lovett-Racke, PhD; Matthew Gormley; Yue Liu, MS; Maria Petracca, MD; Matilde Inglese, MD; Richard Shubin, MD; Sibyl Wray, MD; Michael S. Weiss; Jenna A. Bosco; Sean A. Power; Koby Mok, PhD; James Eubanks, PhD

Presented at the Annual Congress of ECTRIMS, October 11, 2018, Berlin, Germany
Presented analyses included data that were not source document verified.

### Disclosures

#### Research Support:
- TG Therapeutics
- Acorda
- Biogen
- Celgene
- Chugai
- EMD Serono
- MedDay
- Novartis
- Roche-Genentech
- Sanofi Genzyme
- Teva Neuroscience

#### Consultancy/Advisory/Speaker:
- TG Therapeutics
- Acorda
- Bayer
- Biogen
- EMD Serono
- Genentech
- Novartis
- Roche-Genentech
- Sanofi Genzyme
- Teva Neuroscience
Ublituximab (TG-1101)

- Novel Glycoengineered Anti-CD20 mAb
- Unique protein sequence
- Type 1 Chimeric IgG1 mAb
- Potential advantages over current standard of care:
  - Glycoengineered for significantly enhanced ADCC
  - Activity in “low” CD20 expressing cell lines, a characteristic of rituximab resistance
  - Binds to a novel epitope on CD20
  - Infusion times as low as one hour

Source: Adapted from Ruuls et al 2008
Ublituximab Phase 2 RMS: Design

**Primary Efficacy Endpoint:** Responders Rate

Responders Rate = Subjects who have ≥95% B-cell depletion at Week 4
Ublituximab Phase 2 RMS:
Key Inclusion and Exclusion Criteria

Key Inclusion Criteria:
- 18-55 age
- Diagnosis of RMS (McDonald criteria 2010)
- ≥ 2 relapses in prior 2 years or 1 relapse in the year prior to screening and/or ≥1 Gd enhancing lesion
- Active disease
- EDSS 0-5.5 (inclusive)

Key Exclusion Criteria:
- Treatment with Anti-CD20 within last 12 months
- Treatment with alemtuzumab within last 12 months
- Prior DMT exposure within days of screening
  - 90 days with fingolimod and natalizumab
  - 30 days with glatiramer acetate, interferons, dimethyl fumarate, or glucocorticoids
## Ublituximab Phase 2 RMS: Treatment Regimen

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Randomization</th>
<th>Treatment</th>
<th>Day 1/ Infusion Time</th>
<th>Day 15/ Infusion Time</th>
<th>Week 24/ Infusion Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Placebo (n=2)</td>
<td>Placebo / 4h</td>
<td>Placebo / 3h</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>UTX (n=6)</td>
<td>150 mg / 4h</td>
<td>450 mg / 3h</td>
<td>450 mg / 1.5h</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Placebo (n=2)</td>
<td>Placebo / 4h</td>
<td>Placebo / 1.5h</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>UTX (n=6)</td>
<td>150 mg / 4h</td>
<td>450 mg / 1.5h</td>
<td>450 mg / 1h</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Placebo (n=2)</td>
<td>Placebo / 4h</td>
<td>Placebo / 1h</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>UTX (n=6)</td>
<td>150 mg / 4h</td>
<td>450 mg / 1h</td>
<td>600 mg / 1h</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Placebo (n=2)</td>
<td>Placebo / 3h</td>
<td>Placebo / 1h</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>UTX (n=6)</td>
<td>150 mg / 3h</td>
<td>600 mg / 1h</td>
<td>600 mg / 1h</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Placebo (n=2)</td>
<td>Placebo / 2h</td>
<td>Placebo / 1h</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>UTX (n=6)</td>
<td>150 mg / 2h</td>
<td>600 mg / 1h</td>
<td>600 mg / 1h</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Placebo (n=2)</td>
<td>Placebo / 1h</td>
<td>Placebo / 1h</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>UTX (n=6)</td>
<td>150 mg / 1h</td>
<td>600 mg / 1h</td>
<td>600 mg / 1h</td>
<td></td>
</tr>
</tbody>
</table>
## Baseline Demographics

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Subjects and treatment</th>
<th>Age (Years) (^1)</th>
<th>Gender (% Female)</th>
<th>Disease Duration (Years) (^{1,2})</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Placebo (n=2)</td>
<td>39±14</td>
<td>50%</td>
<td>15.5±20.4</td>
</tr>
<tr>
<td></td>
<td>UTX (n=6)</td>
<td>43±12</td>
<td>67%</td>
<td>7.1±7.3</td>
</tr>
<tr>
<td>2</td>
<td>Placebo (n=2)</td>
<td>44±1</td>
<td>0%</td>
<td>0.9±1.2</td>
</tr>
<tr>
<td></td>
<td>UTX (n=6)</td>
<td>33±10</td>
<td>100%</td>
<td>5.3±7.0</td>
</tr>
<tr>
<td>3</td>
<td>Placebo (n=2)</td>
<td>38±7</td>
<td>50%</td>
<td>11.5±7.5</td>
</tr>
<tr>
<td></td>
<td>UTX (n=6)</td>
<td>40±11</td>
<td>67%</td>
<td>13.4±10.0</td>
</tr>
<tr>
<td>4</td>
<td>Placebo (n=2)</td>
<td>31±1</td>
<td>67%</td>
<td>0.2±0.1</td>
</tr>
<tr>
<td></td>
<td>UTX (n=6)</td>
<td>39±12</td>
<td>50%</td>
<td>4.4±5.4</td>
</tr>
<tr>
<td>5</td>
<td>Placebo (n=2)</td>
<td>36±12</td>
<td>100%</td>
<td>15.4±9.6</td>
</tr>
<tr>
<td></td>
<td>UTX (n=6)</td>
<td>46±1</td>
<td>100%</td>
<td>6.3±5.6</td>
</tr>
<tr>
<td>6</td>
<td>Placebo (n=2)</td>
<td>28±1</td>
<td>50%</td>
<td>5.7±2.5</td>
</tr>
<tr>
<td></td>
<td>UTX (n=6)</td>
<td>40±8</td>
<td>33%</td>
<td>8.5±8.4</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>N=48</strong></td>
<td><strong>40±10</strong></td>
<td><strong>65%</strong></td>
<td><strong>7.7±8.1</strong></td>
</tr>
</tbody>
</table>

\(^1\) Mean ± Standard Deviation  
\(^2\) Distribution of time from diagnosis: 22 subjects (46%) were less than 5 years, 10 (21%) were 5-10 years, and 16 (33%) were greater than 10 years
Ublituximab Phase 2 Results: Primary Endpoint – B cell Depletion

- **100% Responders Rate**
  - (48/48) subjects met the primary end point of >95% B-cell depletion from baseline to Week 4, p<0.001

- At Week 4, median 99% B cell depletion was observed and maintained at Week 24 and Week 48
Ublituximab Phase 2 RMS: Safety & Tolerability

Adverse Event Summary*

<table>
<thead>
<tr>
<th></th>
<th>Regardless of Causality n (%)</th>
<th>Related to Ublituximab n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with an Adverse Event (AE)</td>
<td>48 (100%)</td>
<td>12 (25%)</td>
</tr>
<tr>
<td>Patients with a Serious Adverse Event (SAE)</td>
<td>8 (17%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>AEs leading to Withdrawal</td>
<td>1 (2%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

*Excludes Infusion Related Reactions (IRRs)

- Ublituximab was well tolerated and no drug related discontinuations occurred
  - One Grade 3 SAE of fatigue was deemed possibly related to ublituximab
  - No deaths reported on study
  - One subject withdrew from the study due to pregnancy but continued to be followed with safety lab monitoring and immunological analyses
Ublituximab Phase 2 RMS: Safety & Tolerability

Adverse Events (AEs) Related to Ublituximab

<table>
<thead>
<tr>
<th>Event, n (%)</th>
<th>(N=48)</th>
<th>All Grades</th>
<th>Grade 3/4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Most frequently reported adverse events</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infusion Related Reaction</td>
<td>23 (48%)</td>
<td>- (-)</td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>4 (8%)</td>
<td>- (-)</td>
<td></td>
</tr>
<tr>
<td>Dry Throat</td>
<td>1 (2%)</td>
<td>- (-)</td>
<td></td>
</tr>
<tr>
<td>Ear Infection</td>
<td>1 (2%)</td>
<td>- (-)</td>
<td></td>
</tr>
<tr>
<td>Ecchymosis</td>
<td>1 (2%)</td>
<td>- (-)</td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>1 (2%)</td>
<td>1 (2%)</td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td>1 (2%)</td>
<td>- (-)</td>
<td></td>
</tr>
<tr>
<td>Neutropenia</td>
<td>1 (2%)</td>
<td>- (-)</td>
<td></td>
</tr>
<tr>
<td>Oral Herpes</td>
<td>1 (2%)</td>
<td>- (-)</td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td>1 (2%)</td>
<td>- (-)</td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>1 (2%)</td>
<td>- (-)</td>
<td></td>
</tr>
<tr>
<td>Staphylococcal Infection</td>
<td>1 (2%)</td>
<td>- (-)</td>
<td></td>
</tr>
<tr>
<td>Throat Irritation</td>
<td>1 (2%)</td>
<td>- (-)</td>
<td></td>
</tr>
</tbody>
</table>

- Most common Adverse Event (AE) was infusion-related reactions
- No Grade 3/4 Infusion Related Reactions (IRRs)
Ublituximab Phase 2 RMS: Infusion Related Reaction (IRR)

### All IRRs Related to Ublituximab

<table>
<thead>
<tr>
<th>Ublituximab Infusions</th>
<th>Total Patients with ≥1 IRRs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1 (n=48)</td>
<td></td>
</tr>
<tr>
<td>Day 15 (n=48)</td>
<td></td>
</tr>
<tr>
<td>Week 24 (n=46)</td>
<td></td>
</tr>
<tr>
<td>Total IRRs by Day</td>
<td></td>
</tr>
<tr>
<td>21 (44%)</td>
<td>5 (10%)</td>
</tr>
<tr>
<td>7 (15%)</td>
<td>23 (48%)</td>
</tr>
</tbody>
</table>

- IRRs were most frequent with the first infusion (Day 1)
- Day 1 dose infused in ≤3 hours resulted in higher rates of IRRs
- IRRs were infrequent on Day 15 and Week 24 and did not appear to increase with higher doses or faster infusion times
- 77% of total infusions did not result in an IRR

### Day 1 Infusion Time

<table>
<thead>
<tr>
<th>Day 1 Infusion Time</th>
<th>n</th>
<th>Day 1 IRRs</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 hours</td>
<td>24</td>
<td>7 (33%)</td>
</tr>
<tr>
<td>≤3 hours</td>
<td>24</td>
<td>14 (58%)</td>
</tr>
</tbody>
</table>

ULTIMATE Phase 3 Dose
Ublituximab Phase 2 RMS: MRI T1 Gd Enhancing Lesions

**Baseline (n=46):**
- Mean = 3.63 ± 7.80 T1 Gd lesions
- 39% had ≥ 1 T1 Gd lesions
- 26% had ≥ 4 T1 Gd lesions

**Week 24 & Week 48 (n=46):**
- No T1 Gd lesions found in any scans
- 100% reduction from baseline \( (p=0.003) \)

**Subject T1 Gd MRI at Baseline, Week 24 & Week 48**
Ublituximab Phase 2 RMS Results: MRI T2 Lesion Volume

- Decrease of 7.3% in T2 lesion volume at Week 24 compared to baseline and a further decrease of 3.63% from Week 24 to Week 48

- The mean number of new/enlarging (NEL) T2 lesions from baseline to Week 24 was 0.20 ± 0.43 NEL/subject

- The mean number of new/enlarging (NEL) T2 lesions from Week 24 to Week 48 was 0.04 ± 0.29 NEL/subject
At Week 48:

- Annualized Relapse Rate (ARR) of 0.07
  - ARR calculated based on 48 subjects with a mean follow up of approximately 47 weeks (20 min – 48 max weeks)
  - 93% of subjects were relapse free

- 86% of subjects experienced ≥1 relapse in the year prior to screening
- Mean number of relapses = 1.45 Median = 2
Ublituximab Phase 2 RMS Results: Disability

- Mean EDSS at baseline was 2.44 ± 1.36; Median=2.5 (n=48)

- Disability at Week 48:
  - 7% of subjects met criteria for 24 Week Confirmed Disability Progression (CDP)
  - 17% of subjects met criteria for 24 Week Confirmed Disability Improvement (CDI)
Ublituximab Phase 2 RMS Results: NEDA at Week 48

- At Week 48, 46* subjects received all assessments to be evaluated for NEDA:
  - 93% of subjects were relapse free
  - 93% of subjects did not experience 24 week confirmed disability progression (CDP)
  - 100% of subjects did not have any Gd enhancing lesions
  - 83% of subjects did not have any new/enlarging T2 lesions on any scan (either Week 24 or Week 48)
  - 74% of subjects achieved clinical and MRI outcomes consistent with NEDA

* 2 of the total 48 patients did not have Week 24 MRI or EDSS assessments therefore only 46 patients had received all assessments to be evaluated for NEDA

24 Week Confirmed Disability Progression (CDP) is defined as an increase of ≥ 1.0 point from the baseline EDSS score (that is not attributable to another etiology e.g. fever, concurrent illness, or concomitant medication) when the baseline score is 5.5 or less, and ≥ 0.5 when the baseline score is above 5.5, that is confirmed in a subsequent EDSS assessment 24 weeks later

NEDA is defined as subjects without relapses, MRI activities (no T1 Gd+ lesions and no new/enlarging T2 lesions), and no 24-week confirmed disability progression
B cells are efficiently depleted in most patients within 24 hours of receiving the first dose of ublituximab
  - Median 99% B cell depletion was observed at Week 4, and maintained at Week 24 and Week 48

Ublituximab was well tolerated and the most frequent AEs (all Grade 1 or 2) were Infusion Related Reactions (IRRs)

No study discontinuations related to ublituximab
At Study Conclusion (Week 48 of Ublituximab Treatment):
- Annualized Relapse Rate (ARR) of 0.07
- 93% of subjects were relapse free
- No T1 Gd enhancing lesions were detected in any subjects at Week 24 or at Week 48
- 74% of subjects fulfilled the criteria for NEDA

A rapid infusion time, as low as one hour, of 450mg ublituximab was well tolerated, produced high levels of B cell depletion and is now being studied in the Phase 3 ULTIMATE trials
ULTIMATE I and II Study Design

- **Primary Endpoint:** Annualized Relapse Rate (ARR) at 96 weeks in RMS subjects treated with ublituximab

- **Enrollment complete in the ULTIMATE Phase 3 Program**
Thank You to Our Study Sites and Their Patients

- Hope Neurology, Knoxville, TN: Sibyl Wray, MD
  - Coordinator: Brenda Whitehead, CCRP
- SC3 Research Group, Arcadia, CA: Richard Shubin, MD
  - Coordinator: Ngoc Nguyen
- Ohio State University, Columbus, OH: Richard Kissel, MD
  - Coordinator: Misty Green
- Associates in Neurology, Lexington, KY: Cary Twyman, MD
  - Coordinator: Laura Sanders, CCRC
- Central Texas Neurology, Round Rock, TX: Edward Fox, MD, PhD
  - Coordinator: Lori Mayer, RN, DNP
- University of Colorado, Aurora, CO: Timothy Vollmer, MD
  - Coordinator: Emil Diguilio
- Neurology Center of San Antonio, TX: Ann Bass, MD
  - Coordinator: Tina Clements, RN, MSN
- Holy Name Hospital, Teaneck, NJ: Mary Ann Picone, MD
  - Coordinator: Stacey Melvin, RN, BSN